Aision: Prophylactic drugs to prevent the development of stress-induced mood and anxiety disorders
Unmet Medical Need: Affective disorders, such as major depressive disorder and post-traumatic stress disorder (PTSD), are currently treated from a symptom-suppression approach. Existing drugs only mitigate symptomatology, but do not cure or prevent the chronic disease itself.
Envisioned Healthcare Product: The team is developing the first drugs that would prevent the development of stress-induced psychiatric disorders. The target product is an orally available, single dose short-acting small molecule that provides at least one month of stress resilience enhancement, decreasing the incidence of PTSD by at least 20%. This represents a paradigm shift in psychiatry; using pharmacotherapy to prevent mental illness.
Stage of Development: Animal testing
Funding Cycle: 2017-2018